Is constipation common with semaglutide?
Constipation is a recognized adverse reaction. In the adult weight-reduction trials summarized in the Wegovy label, it was reported by 24% of people receiving the 2.4 mg injection and 11% receiving placebo. These figures concern the labeled trial population and formulation; they should not be copied to every semaglutide product, dose or use.[1]
“Common” describes how often a symptom was reported. It does not tell you how severe yours is, whether another cause is involved, or how long it is reasonable to wait. A familiar side effect can still merit a clinical conversation. The useful task is to describe what changed from your usual pattern and whether other symptoms are present.
Frequency is only one part of the story
Describe the problem beyond the calendar
NIDDK describes constipation through several features: fewer bowel movements, hard or dry stools, painful or difficult passage, or a sense that stool has not fully passed. The condition is not defined by frequency alone.[2]
| What to separate | What it means for your reading |
|---|---|
| Your usual pattern | Explain what is different rather than assuming there is one normal schedule. |
| Stool and discomfort | Mention hardness, straining, pain or an incomplete feeling. |
| Timing and medicines | Report when it began and all recent medicine or supplement changes. |
| Associated symptoms | Describe vomiting, abdominal pain, bleeding or inability to pass gas promptly. |
You do not need to count every detail indefinitely. The aim is to give the clinician enough context to decide what should happen next. If you have already tried something, name the product and how you used it. This helps avoid overlapping treatments and makes the response easier to interpret. A message that only says “still constipated” leaves out information the care team may need.
For another commonly discussed symptom, read tirzepatide and fatigue. Use the provider checklist to ask how a service handles new symptoms. Our nausea guide covers eating difficulties and clinical contact.
What general guidance can—and cannot—do
NIDDK’s general treatment guidance discusses gradually increasing dietary fiber, drinking liquids as appropriate, regular physical activity and a regular opportunity for bowel movements. It also describes clinician-directed medicine changes and laxative options. Which approach fits depends on the cause and the person; its advice is not a semaglutide-specific regimen.[3]
Ask your clinician or pharmacist how that general advice fits your health history and existing treatment. A fixed fluid target, supplement stack or laxative schedule from a web page may not account for other conditions or medicines. If symptoms persist, the next step is assessment rather than repeatedly escalating a self-selected remedy. Do not adjust a prescription simply to fit an online timetable.
The Wegovy label also warns that gastrointestinal reactions can be severe and instructs patients to report severe or persistent stomach problems. That warning should remain visible beside the common-side-effect table. A trial frequency does not establish the right response to an individual episode.[1]
Symptoms that should not wait
NIDDK advises seeing a doctor right away for constipation with rectal bleeding or blood in the stool, constant abdominal pain, inability to pass gas, vomiting, fever or unintentional weight loss. These signs call for medical evaluation rather than assuming the medicine is the explanation.[2]
For a severe or rapidly worsening situation, use urgent or emergency services rather than waiting in a routine message queue. A provider should make that distinction clear when you enroll. Knowing the contact route before a problem develops is part of choosing a service, especially when care is primarily online. An automated acknowledgement confirms a message arrived; it does not confirm a clinician has assessed it.
Build a follow-up plan you can use
Ask the care team what information to send, who reviews it, and how you will know whether an appointment is needed. If an initial plan is suggested, ask when to check back if it does not help and which changes mean contacting them sooner. This gives the conversation a next step without asking the patient to infer a monitoring plan from a side-effect list.
Use the provider checklist to compare those arrangements and the semaglutide provider guide to organize a shortlist. The Hers review is one service-specific place to examine messaging and ongoing-care questions. The trial evidence does not establish which provider handles symptoms best; the comparison concerns documented services, with clinical suitability decided individually.
Longer-term planning includes comfort and tolerability as well as price. Our semaglutide withdrawal explainer provides context for a prescriber-led discussion if treatment becomes difficult to continue. Report the problem and discuss the options instead of treating a subscription renewal as the only available decision point.
Sources
- Wegovy (semaglutide), FDA prescribing information revised February 2026, sections 5, 6.1 and Medication Guide. Adult injection weight-reduction trials: semaglutide 2.4 mg n=2,116 versus placebo n=1,261, up to 68 weeks; manufacturer Novo Nordisk. Rates below concern that injection-trial population, not every formulation or indication. NIDDK: Symptoms & Causes of Constipation; Treatment for Constipation. Label data describe group reports, not individual cause or severity. ↩
- NIDDK: symptoms and causes ↩
- NIDDK: treatment ↩